Indian Pharma in September 2025: Momentum, Disruption & Caution

By Anup Soans

October 8, 2025

By MedicinMan Editorial Team
Published: October 2025

💊 Introduction

September 2025 marked a turning point for India’s pharmaceutical industry. The market continued to grow in value despite regulatory tremors, safety controversies, and global trade pressures. On the brighter side, innovation and chronic-care therapies kept fueling demand, signaling long-term resilience.

Free Membership Required

You must be a Free member to access this content.

Join Now

Already a member? Log in here

Hot this week

Topics

Vivek V. Kamath Appointed CEO at PlasmaGen BioSciences

Pharma GCCs – What Used to Happen in Boston or Basel Now Happens in Bangalore

Indian Pharma in September 2025: Momentum, Disruption & Caution

💊 Introduction

Free Membership Required

Evonile Pharma: The Real Bet Is Not the Acquisition. It is the Field Force.

Closing the Value Gap in Indian Pharma: What Doctors Really Want from Digital Engagement

Indian Pharma 2026: The Growth Engine Is Changing

Anand Shetty Appointed CEO – Emerging Markets at Cadila Pharmaceuticals

The paradox of the “Pharmacy of the World.” 💊

Topics

Evonile Pharma: The Real Bet Is Not the Acquisition. It is the Field Force.

Closing the Value Gap in Indian Pharma: What Doctors Really Want from Digital Engagement

Indian Pharma 2026: The Growth Engine Is Changing

Anand Shetty Appointed CEO – Emerging Markets at Cadila Pharmaceuticals

The paradox of the “Pharmacy of the World.” 💊

The Innovator’s Gene and the Generic’s Promise

Private Equity in Indian Healthcare: Who Is Investing Beyond the Metros?

Anuj Pasrija Elevated to Country Lead, J&J MedTech India and Vice President – Surgery

Related Articles

What’s Killing Patients? Cancer or Rigged Drug Prices?

Medical Reps—Lessons From The West: The Old Model is Dead

The Great Healthcare Pivot: Who Owns The Consumer Before They Become A Patient?

RPG-Raghava and Lessons From a Decade of Indian Pharma M&A

Pharmacy of the World Pricing Paradox

Company

Headlines

Evonile Pharma: The Real Bet Is Not the Acquisition. It is the Field Force.

Closing the Value Gap in Indian Pharma: What Doctors Really Want from Digital Engagement

Indian Pharma 2026: The Growth Engine Is Changing

Anand Shetty Appointed CEO – Emerging Markets at Cadila Pharmaceuticals

Newsletter